Help prevent hereditary angioedema (HAE) attacks with ORLADEYOTM (berotralstat)

ORLADEYO provides meaningful attack prevention

In a 6-month study of 120 adolescents and adults with HAE, 40 were given ORLADEYO 150 mg, 41 were given ORLADEYO 110 mg, and 39 were given placebo.

Attack rate was lowered by 44% for those taking ORLADEYO 150 mg compared with placebo.

The use of rescue therapy was cut by more than half in people taking ORLADEYO 150 mg compared with placebo.a

aThese data are from an ad hoc analysis.

ORLADEYO provides long-lasting attack prevention

Among 31 people who completed the 6-month study and went on to take ORLADEYO 150 mg for a total of 12 months, their average number of attacks per month dropped considerably.

Reported reduction in HAE attack rates after 12 months on ORLADEYO™ Reported reduction in HAE attack rates after 12 months on ORLADEYO™

Another clinical study looked at the long-term safety as well as the effectiveness of ORLADEYO. In this study, more than half of the first 73 people to finish 12 months of treatment had 0 attacks in 5 of the last 6 months of treatment.